The Cocktail Report (sound really smart around your friends):
Altos Labs is a $3 billion biotech company backed by some of the world's wealthiest individuals, with four Nobel laureates on staff and a singular mission: not to treat aging, but to reverse it at the cellular level.
Chief Scientific Officer Juan Carlos Izpisua argues that aging is fundamentally a process called epithelial-mesenchymal transition (EMT), in which cells progressively lose their identity, forgetting what type of cell they are and how to function properly.
This cellular identity loss is, according to Izpisua's latest research, the earliest measurable sign of aging: it precedes mitochondrial deterioration and telomere shortening and drives the fibrosis (scarring of tissue) that underlies dozens of age-related diseases.
His team's intervention is partial cellular reprogramming: activating Yamanaka factors (genes that can reset a cell's developmental clock) for just two days per week, reversing age-related damage across multiple organs in mice without triggering tumor formation.
In more than 7,000 treated mice, the researchers observed zero cases of uncontrolled cellular regression into embryonic-like tumor-forming states, a major safety concern the field has long worried about.
Most people think of aging as the body slowly wearing out, like a car accumulating miles. A leading researcher at the world's best-funded longevity laboratory has a different and more precise answer: your cells are losing their identity.
Juan Carlos Izpisua, Chief Scientific Officer of Altos Labs and one of the world's most cited scientists in cellular reprogramming, presented his latest research at Spain's Royal National Academy of Medicine this week. His central argument reframes aging at the molecular level.
The process he points to is called epithelial-mesenchymal transition (EMT), a biological mechanism that is essential during embryonic development, allowing cells to migrate and form the body's organs. After roughly age 30, this same process becomes dysregulated, causing cells to blur their specialized functions and drift toward a generic, stressed state.
"Aging is a loss of identity at the cellular level," Izpisua said. According to his team's analysis of the UK Biobank (a database of biological samples from more than half a million volunteers), blood proteins linked to this cellular drift are the markers most strongly associated with mortality across human diseases.
The identity loss precedes even mitochondrial decline and telomere shortening, meaning it may be the earliest point at which the aging process becomes detectable and, potentially, reversible.
The treatment Izpisua's lab is testing is partial cellular reprogramming. By briefly activating Yamanaka factors (a set of genes capable of resetting a cell's developmental clock) for two days per week, rather than continuously, his team can push aged cells back toward a more youthful functional state without erasing their identity.
In experiments spanning more than 7,000 mice, the intervention reversed liver and metabolic damage, regenerated muscle tissue, and produced measurable lifespan extension. Critically, not a single animal developed tumors from uncontrolled cellular regression, which has been the field's primary safety concern.
"We have treated more than 7,000 mice and in no case have we seen differentiation into an embryonic cell," Izpisua said.
"A single intervention has effects across the organism," he continued. "We are touching the heart of the process that gives rise to disease."
The next step is human-adjacent. In collaboration with Hospital Clínic de Barcelona, Izpisua's team will apply partial reprogramming to donor organs deemed unsuitable for transplantation, testing whether damaged tissue can be repaired enough to become viable.
No patients are being treated yet, but the experiment represents the first bridge between animal results and eventual human application.
Why Should You Care?
Altos Labs is not a fringe operation: it has $3 billion in funding, four Nobel laureates, and has recruited some of the most accomplished biologists in the world away from top universities.
When its chief scientist presents a unified theory of aging supported by data from half a million human biosamples, that is worth paying attention to.
The cellular identity framework also has practical implications: if the earliest measurable sign of aging is EMT-driven cellular drift, it suggests that future aging biomarkers and interventions will target identity loss long before conventional signs of decline appear.
Sources:
1. El País — "Longevity researcher Juan Carlos Izpisua presents latest data on aging process: 'It is a loss of identity at the cellular level'" (May 25, 2026): https://english.elpais.com/science-tech/2026-05-25/longevity-researcher-juan-carlos-izpisua-presents-latest-data-on-aging-process-it-is-a-loss-of-identity-at-the-cellular-level.html
2. Altos Labs: https://www.altoslabs.com
